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Continuous performance test impairment
in a 22q11.2 microdeletion mouse model:
improvement by amphetamine
Simon R. O. Nilsson1,2,3,4, Christopher J. Heath5, Samir Takillah 6,7,8,9,10, Steve Didienne8, Kim Fejgin11, Vibeke Nielsen11,
Jacob Nielsen11, Lisa M. Saksida1,2,12,13,14, Jean Mariani 9,10, Philippe Faure7, Michael Didriksen11, Trevor W. Robbins1,2,
Timothy J. Bussey1,2,12,13,14 and Adam C. Mar3,4
Abstract
The 22q11.2 deletion syndrome (22q11.2DS) confers high risk of neurodevelopmental disorders such as schizophrenia
and attention-deﬁcit hyperactivity disorder. These disorders are associated with attentional impairment, the
remediation of which is important for successful therapeutic intervention. We assessed a 22q11.2DS mouse model (Df
(h22q11)/+) on a touchscreen rodent continuous performance test (rCPT) of attention and executive function that is
analogous to human CPT procedures. Relative to wild-type littermates, Df(h22q11)/+ male mice showed impaired
attentional performance as shown by decreased correct response ratio (hit rate) and a reduced ability to discriminate
target stimuli from non-target stimuli (discrimination sensitivity, or d’). The Df(h22q11)/+ model exhibited decreased
prefrontal cortical-hippocampal oscillatory synchrony within multiple frequency ranges during quiet wakefulness,
which may represent a biomarker of cognitive dysfunction. The stimulant amphetamine (0–1.0 mg/kg, i.p.) dose-
dependently improved d’ in Df(h22q11)/+ mice whereas the highest dose of modaﬁnil (40 mg/kg, i.p.) exacerbated
their d’ impairment. This is the ﬁrst report to directly implicate attentional impairment in a 22q11.2DS mouse model,
mirroring a key endophenotype of the human disorder. The capacity of the rCPT to detect performance impairments
in the 22q11.2DS mouse model, and improvement following psychostimulant-treatment, highlights the utility and
translational potential of the Df(h22q11)/+ model and this automated behavioral procedure.
Introduction
A copy number variant (CNV) composed of a hemi-
zygous microdeletion at chromosomal locus 22q11.2
confers large genetic risk for schizophrenia1, attention-
deﬁcit hyperactivity disorder (ADHD)2 and autism3. The
22q11.2 microdeletion syndrome (22q11.2DS) and its
related neuropsychiatric disorders are associated with
executive and attentional impairments4. These deﬁcits are
of central interest for translational5 and genetic studies6
aimed at discovering more effective therapeutics.
Attentional and executive dysfunctions are commonly
evaluated using computerized continuous performance
tests (CPTs)7. Typically, visual target or non-target stimuli
are brieﬂy presented at a ﬁxed screen location across a
series of continuous, sequential trials. The subject is
required to rapidly respond to targets and withhold from
responding to non-targets. Non-affected individuals with
high genetic load of schizophrenia-related genetic var-
iants8, and 22q11.2 deletion carriers7,9–12, show impaired
CPT performance. These impairments predict functional
outcome11,13, appear independent of general intelligence9,
and are often unaffected by available therapeutics14.
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Deﬁcits in CPT performance are therefore important
targets for therapeutic discovery efforts.
Several mouse models of 22q11.2DS have been gener-
ated15–19. Studies investigating the performance of these
models across multiple cognitive domains, including
associative and spatial learning, ﬂexibility, and memory,
have yielded equivocal results19–23. One of the consistent
behavioral impairments in these models is an acquisition
deﬁcit on a T-maze delayed non-match to position
task19,23–25. This deﬁcit has been commonly ascribed to
an impairment in working memory and has been linked to
prefrontal cortical (PFC)-hippocampal asynchrony
within theta and gamma bands20,24. However, the T-maze
impairment in the 22q11.2DS mouse model
appears transient and delay-independent—inconsistent
with a primary deﬁcit in working memory23. PFC-
hippocampal synchrony is also associated with executive
function and/or attentional processes in other behavioral
paradigms26–28.
There is a paucity of studies evaluating attentional
function in 22q11.2DS mouse models29. One recent study
assessed divided visuospatial attention using the 5-choice
serial reaction time task (5-CSRTT) and reported either
no effect, or paradoxically improved performance after
extended training, in the Df(h22q11)/+ model23. How-
ever, to date, there have been no assessments of focused
visual attention in 22q11.2DS mouse models. In 22q11.2
deletion carriers, assessments by CPTs and related para-
digms demonstrate clinically-relevant impairments on
measures of correct response ratio (hit rate) and ability to
discriminate target stimuli from non-target stimuli (signal
detection sensitivity, or d’)7,9–12.
As part of the NEWMEDS initiative (Innovative Medi-
cines Initiative Grant Agreement No. 115008), the current
study assessed executive and attentional function in two
cohorts of a 22q11.2DS mouse model (Df(h22q11)/+) and
wild-type littermates. We evaluated aspects of focused
attention and inhibitory control using a touchscreen
rodent continuous performance test (rCPT) that has been
developed to closely emulate the human paradigm30,31.
The rCPT is experimenter-paced and features multiple
complex luminance-matched target and non-target sti-
muli that require detection and discrimination as well as
response inhibition31. We hypothesized that the rCPT
would be sensitive for identifying attentional impairment
in the Df(h22q11)/+ model as measured by d’ and/or hit
rate. To further characterize the Df(h22q11)/+ mouse
model, we investigated PFC-hippocampal coherence
which has been proposed as an endophenotype of several
neuropsychiatric disorders associated with 22q11.2DS,
including schizophrenia32. PFC-hippocampal synchrony
has been shown to be disrupted in another 22q11.2DS
mouse model (Df(16)A+ /−) while animals are perform-
ing a maze task20,24. We probed the robustness and
generalizability of this potential endophenotype by eval-
uating PFC-hippocampal synchrony in a separate cohort
of Df(h22q11)/+ mice under quiet-wake “baseline” con-
ditions, independent of potentially confounding inﬂu-
ences of prior cognitive training or ongoing behavioral
performance. Finally, we assessed the effect of acute sys-
temic modaﬁnil and amphetamine treatments in the (Df
(16)A+ /−) model on rCPT performance. The behavioral
effects of these drugs have been shown to diverge
depending on dose to produce characteristic U-shaped
response curves33 with beneﬁcial effects of acute low-dose
amphetamine or modaﬁnil frequently being reported on
tests of attention and response control in both humans
and experimental animals34–36. Moreover, the psychosti-
mulant methylphenidate has been demonstrated to
acutely improve discrimination sensitivity, d’37, decrease
target omissions and increase hits38 on CPTs in indivi-
duals with 22q11.2DS. Based on this evidence we hypo-
thesized that both amphetamine and modaﬁnil would
improve d’ and/or hit rate of the Df(h22q11)/+ model in
the rCPT.
Method
Animals
The generation of Df(h22q11)/+ mice is described
elsewhere39. Animals for these experiments were gener-
ated by mating wild-type C57BL/6N females with hemi-
zygotic Df(h22q11)/+ males. Young (7–8 weeks), male Df
(h22q11)/+ and wild-type littermate offspring were ran-
domly selected and shipped to Cambridge and UPMC for
experimentation. Figure 1 depicts the experimental
timeline of this study. The behavioral experiments were
performed at the University of Cambridge and used two
cohorts of male mice housed as previously described23.
Sample sizes were selected based on previous rCPT
experiments30 and similar touchscreen paradigms40. One
cohort of young-adult mice was trained on a progressive
ratio (PR) paradigm (aged 9 weeks at start of testing; wild-
Fig. 1 Timeline illustrating the experimental treatments and ages
of the three cohorts of animals assessed in these experiments.
See Methods for further description of these cohorts
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type N= 16, Df(h22q11)/+N= 15) and subsequently
tested on the rCPT (aged 21 weeks at start of testing, wild-
type N= 13, Df(h22q11)/+N= 15). Another cohort of
older mice (aged 16 months at the start of rCPT testing;
wild-type N= 16, Df(h22q11)/+N= 12) was assessed on
the rCPT after extensive prior cognitive testing23. Animals
were food restricted to about 85% of their free-feeding
weight prior to behavioral testing. The electro-
physiological studies were performed at UPMC Paris and
used 16 male mice aged 3–7 months at testing (wild-type
N= 8, Df(h22q11)/+N= 8). All experiments were con-
ducted in accordance with the European Union regulation
(directive 2010/63 of 22 September 2010) and the UK
Animals (Scientiﬁc Procedures) Act 1986.
Drugs
Modaﬁnil (Eli Lilly, USA; 0, 0.4, 4.0, 40 mg/kg, i.p,
30 min pretreatment time) was dissolved in vehicle (0.9%
sterile saline and 0.5% arabic gum). d-Amphetamine sul-
phate (Sigma Aldrich, UK; 0, 0.25, 0.5, and 1.0 mg/kg, i.p;
20 min pretreatment time) was dissolved in vehicle (0.9%
sterile saline). Dosing protocols were based on previous
unpublished and published experiments41–43.
Procedure
Behavioral procedures
See Supplementary Material for video clips of the
apparatus and of animals performing the touchscreen
rCPT and PR.
Apparatus
The apparatus is described elsewhere40. Brieﬂy, the
experiments used touchscreen chambers (Campden
Instruments, UK) controlled via commercial (PR; ABET
II, Lafaytte Instruments, USA) or in-house software
(rCPT; VB.NET 2010, by A.C.M.). The PR task used a 5-
aperture mask and the rCPT used a 3-aperture mask as
described elsewhere30,41. Animals were trained to
approach the touchscreen as detailed previously40.
The rodent continuous performance test
Training—stage 1 (white-square) The rCPT training
procedure is described in detail elsewhere30,31. Brieﬂy,
each trial began with a 2 s inter-stimulus interval (ISI)
prior to stimulus presentation. To discourage superﬂuous
responding to the screen, the ISI restarted if the subject
touched the stimulus window during the ISI (‘ISI touch’).
After the ISI, a white-square stimulus was presented for a
10 s stimulus duration (SD). If the animal touched the
stimulus window within the ‘limited hold’ (LH) period
after stimulus onset (LH:10.5 s), a reward (20 μl straw-
berry milkshake) was delivered coupled with white-noise
(1 s) and magazine light illumination. Following the LH
period (non-rewarded trials) or reward collection
(rewarded trials), the next ISI was initiated. Trials were
presented continuously until the session/phase criterion
of 60 rewards was reached (one session for all animals).
Training—stage 2 (1-stimuli) The correct stimulus (CS
+: vertical or horizontal lines, counterbalanced across
genotypes) was presented for a 5 s SD (LH:5.5 s). A 5 s
delay to allow for reward consumption was added
following reward collection. Other parameters remained
identical to stage 1. All animals achieved criterion in a
single session.
Training—stage 3 (2-stimuli) On each trial, the mouse
was presented with either the CS+ or a novel incorrect
stimulus (CS−). The CS+ was identical to stage 2 while
the CS− was a ‘snowﬂake’ stimulus30. The SD was
reduced to 2.5 s (LH:2.5 s), the ISI was increased to 5 s and
the CS+ probability was 50%. After a response to the CS
−, a correction trial was implemented where the CS− was
presented again following the ISI. Correction trials were
presented until the animal successfully omitted a response
to the CS−. The session ended after 100 correct responses
or 45min, whichever occurred ﬁrst. Other parameters
remained the same as in stage 2. The animals progressed
as a group to the baseline rCPT procedure after 5 sessions
on stage 3. All animals were performing at d’ greater than
0.6 criterion30.
Baseline rCPT (5-stimuli) On each trial, animals were
presented with one of ﬁve stimuli: four non-targets and
the stage 3 target30. Other parameters remained identical
to stage 3. Animals in the younger cohort were assessed
for 6 sessions prior to acute, systemic treatment with
modaﬁnil and then amphetamine, using randomized
Latin-square designs. The older cohort was assessed on
baseline rCPT for 2 sessions followed by a series of probe
tests (See Supplementary Material).
Progressive ratio
As motivational capacity can inﬂuence cognitive task
performance, we also assessed Df(h22q11)/+ mice in a
progressive ratio (PR) task. Animals in the younger cohort
were tested in a touchscreen PR task designed to assess
motivation through response requirements that increase
according to linear ramp schedules (PR4-PR16) which is
described elsewhere41.
Electrophysiology
Surgery Mice were anesthetized with ketamine/xylazine
and placed in a stereotaxic frame. Anesthesia was main-
tained with 3% isoﬂurane. Bipolar stainless steel electrodes
were implanted bilaterally at coordinates relative to bregma
in the infralimbic/prelimbic area of the PFC (dorsal-ventral:
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−1.55, anterior-posterior: +1.6, medial-lateral: ±0.5mm)
and CA1 region of the dorsal hippocampus (dorsal-ventral:
−1.20, anterior-posterior: −1.94, medial-lateral: ± 1.2mm).
Monopolar ground electrodes were laid over the
cortical layer of the cerebellum (anterior-posterior: + 6.24,
medial-lateral: ± 1.0mm) and olfactory bulb (anterior-
posterior: + 4.2, medial-lateral: ±0.5mm). Electrodes were
ﬁxed to the skull with dental acrylic and connected to an
electrode interface board (8 channel headstage EIB-8;
Neuralynx, USA). Antiseptic (Povidone-iodine) and local
anesthetic (lidocaine) solutions were applied post-surgery.
Animals were permitted to recover until regaining pre-
surgery body weight.
Signal recording Recordings were done as previously
described44. Brieﬂy, recordings were done in animals
using chambers that limited, but did not restrain move-
ment, and were electrically and acoustically insulated and
isolated from odors and the experimenters. A cold light
(100lux) was placed 20 cm in front of the animal. This
environment was used to minimize the known modula-
tory effects of spontaneous motor activity on hippocampal
local ﬁeld potentials (LFP)45. Animals were gradually
acclimated to the recording set-up and procedure. Wild-
type and Df(h22q11)/+ mice were assessed simulta-
neously (4 mice per genotype) using a Latin-square
design and recordings were made at the same time each
day to minimize circadian LFP effects. Baseline LFP
recordings were obtained over 60 min using a Digital Lynx
SX (Neuralynx) and were acquired with a cheetah32 data
acquisition system (Neuralynx). No attempts to escape or
notable stress reactions were observed (i.e. defecation,
urination, freezing) during the recording sessions.
Signal analysis Data were analyzed using Matlab (Math-
Works®, USA) built-in functions and the Chronox
toolbox46. LFPs were (i) acquired at 1000 Hz and ofﬂine
band-pass ﬁltered at 0.1–100 Hz with zero-phase shift
ﬁlter function (zero-phase digital ﬁltering ﬁltﬁlt function),
and (ii) de-rendered using local linear regression (locde-
trend function from the Chronux toolbox:46 window-size
1 s, overlap 0.5 s) to remove slow drifts, and (iii) notch-
ﬁltered (iirnotch function) with notch located at 50 Hz to
remove possible power line noise. The LFP signal was
expressed in z-score units. The z-score normalization
used the mean and the standard deviation from baseline
(entire rest session) of each electrode. Power spectral
density (PSD) of LFP data was calculated using the
multitaper spectrogram method from the Chronux tool-
box with time-bandwidth product of 5 and 10 slepian
sequences of orthogonal data tapers (window-size 5 s, 2 s
overlap). PSD was averaged over two similar brain regions
(right and left hemisphere) for each frequency and time-
bin. The multitaper coherogram method was used to
calculate coherence (normalized spectral covariance)
between the LFP from two structures with time-
bandwidth product of 30 and 60 slepian sequences of
orthogonal data tapers using a 30 s window-size without
overlap. The signal was bandpass-ﬁltered to extract theta
oscillations by applying a 5–10 Hz ﬁnite impulse response
bandpass with zero-phase shift ﬁlter function (ﬁltﬁlt
function).
Statistical analysis
Behavior
rCPT hit rate was calculated as the ratio of target
responses to target presentations. False alarm rate was
calculated as the ratio of non-target responses to non-
target presentations. The performance was evaluated
using the signal detection measures of discrimination
sensitivity (d’) and response criterion (c)47. The dis-
crimination sensitivity index (d’) assesses the subject’s
capacity to distinguish the target from the non-target
stimuli. The response criterion index (c) assesses the
subject’s propensity or willingness to respond to any sti-
mulus (e.g., target or non-target). Discrimination sensi-
tivity d’ was calculated as48
d′ ¼ z hit rateð Þ  z false alarm rateð Þ ð1Þ
with higher values denoting better ability to discriminate
between target and non-target stimuli. Response criterion
c was calculated as48
c ¼ 0:5 z hit rateð Þ þ z false alarm rateð Þð Þ ð2Þ
with higher values denoting decreased responding to both
target and non-target stimuli. ISI touch rate was calcu-
lated as the number of touches to the response window
during the ISI divided by the total ISI time in minutes.
Incorrect and correct response latency and reward latency
were also collected. Sessions were further split into 50-
trial bins and dependent variables were calculated within
each bin. The measures in the PR test were break-point
(deﬁned as the number of stimulus responses made in the
last successfully completed trial in a session), total tou-
ches, total trials, time-out time, and ‘blank’ touches
(deﬁned as responses to the four never-illuminated
response locations) per minute41. The experimenter was
not blinded to the genotypes/drug-treatments. However,
all behavioral data acquisition and analysis were fully
automated with no experimenter involvement. Drug-free
rCPT and PR data were analyzed by mixed-model
ANOVAs with genotype as the between-subjects factor
and session, SD, ISI, target probability or stimulus con-
trast as within-subjects factors. To analyze our a priori
hypothesis that the deﬁcits in rCPT performance observed
in Df(h22q11)/+ mice could be ameliorated by modaﬁnil
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or amphetamine, the pharmacological data were analyzed
speciﬁcally in Df(h22q11)/+ mice using one-way ANO-
VAs with dose as independent within-subjects factor. To
assess the overall effect of these compounds across all
animals, the data were also analyzed across both geno-
types using mixed-model ANOVAs with genotype as a
between-subjects factor and dose as a within-subjects
factor. Dose-response patterns were also tested for linear
and U-shaped (quadratic) effects31. Signiﬁcant interac-
tions and dose-response patterns were followed by simple
main effect comparisons using one-way ANOVA.
Electrophysiology
Three bands of the PSD were analyzed for each struc-
ture: 0.1–3 Hz (delta), 6–12 Hz (theta) and 30–80 Hz
(gamma). All datasets were tested for normality using
Shapiro-Wilk tests. For multiple comparisons of normally
distributed data we used mixed-model ANOVAs (e.g.,
with frequency bands and genotype as factors). For data
with non-Gaussian distributions, we used non-parametric
Friedman tests. Post-hoc tests (independent-samples t-
tests or Wilcoxon rank-sum test) were performed to
compare genotype PSD and coherence estimates to
identify frequency bands differing in spectral analysis. The
stepwise Holm-Bonferroni (H-B) algorithm was used to
correct for family-wise error rate (i.e., potential inter-
ference during multiple comparisons) by ordering p-
values and adjusting signiﬁcance level α. Standard error
(SEM) intervals were calculated through a jackknife
method46.
Results
The rodent continuous performance test
See Supplementary Tables S1–S5 for detailed statistical
analysis. rCPT performance of young (aged 21 weeks at the
start of testing) Df(h22q11)/+ and wild-type mice is pre-
sented in Fig. 2a–d. Training stages 1 and 2, during which
no non-target stimuli were presented, did not reveal any
effects of genotype (Table S1). When a single, non-target
stimulus was introduced, the Df(h22q11)/+ mouse exhib-
ited a near-signiﬁcant decrease in discrimination sensitivity
(d’) (Fig. 2a; F1,26= 4.203, p= 0.051), a signiﬁcantly
decreased hit rate (Fig. 2b; F1,26= 9.552, p= 0.005) and an
increased response criterion (c) (Fig. 2a; F1,26= 6.971, p=
0.014) relative to wild-type littermate controls. On the
baseline 5-stimulus rCPT, the Df(h22q11)/+model showed
decreased d’ (Fig. 2c; F1,26= 5.724, p= 0.030) and decreased
hit rate (Fig. 2d; F1,26= 4.578, p= 0.042) compared to wild-
type littermate controls. Time-bin analysis showed that Df
(h22q11)/+ mice exhibited impairments throughout the
session (data not shown).
A second older cohort of Df(h22q11)/+mice (aged
70 weeks at start of testing), with extensive previous
cognitive testing experience, also showed decreased target
hit rates when challenged with shorter stimulus durations
(Supplementary Fig. S1a–b; genotype × SD: F5,130= 4.795,
p < 0.0001) and increased response criterion c when
challenged with longer ISI times (Supplementary Fig.
S2c–d; genotype × ISI: F2,50= 3.221, p= 0.048). See Sup-
plementary Material and Results from this cohort of Df
(h22q11)/+ mice when tested on a range of different
probe tests.
Electrophysiological recordings
PFC-hippocampal coherence data are presented in Fig. 3.
See Supplementary Figures S2–S4 for additional analyses.
Representative PFC and hippocampal LFP traces are shown
in Fig. 3a. PFC-hippocampal coherence was reduced in Df
(h22q11)/+ mice (Fig. 3c; genotype: F1,36= 16.190, p <
0.001). Post-hoc analyses showed PFC-hippocampal
coherence reductions in the delta (p= 0.030, t-test, H-B
corrected) theta (p= 0.0027, t-test, H-B corrected) and
gamma (p= 0.0035, Wilcoxon rank-sum, H-B corrected)
bands of Df(h22q11)/+ mice. Genotype did not affect LFP
frequency contents in the PFC (Fig. 3b, left; χ2= 0.09, p=
0.762, Friedman ANOVA) or hippocampus (Fig. 3b, middle;
F1,42= 7.04, p= 0.601, two-way ANOVA).
Effects of pharmacological interventions on continuous
performance
Modaﬁnil in the Df(h22q11)/+ model
The effect of modaﬁnil in the rCPT is presented in Fig.
4a, b and Table 1. In Df(h22q11)/+ mice, modaﬁnil
decreased discrimination sensitivity (d’) and incorrect
response latency. For d’ (Fig. 4a), there was a signiﬁcant
linear effect of dose (F1,14= 4.947, p= 0.043), with mod-
aﬁnil dose-dependently decreasing d’. The highest 40 mg/
kg dose did not signiﬁcantly reduce d’ relative to vehicle
(p= 0.075) but signiﬁcantly reduced d’ relative to the
0.4 mg/kg dose (p= 0.021). On incorrect response latency
(Table 1), there was a signiﬁcant main effect of dose (F3,42
= 3.780, p= 0.017) and a signiﬁcant linear effect of dose
(F1,14= 7.184, p= 0.018), with modaﬁnil dose-
dependently reducing incorrect response latency. The
40mg/kg dose decreased incorrect response latency
relative to vehicle (p < 0.0001) and the 4.0 mg/kg dose (p
< 0.019).
On false alarm rate (Fig. 4b), there was a signiﬁcant U-
shaped dose-response (F1,14= 5.508, p= 0.034). However,
post-hoc analyses comparing each dose were not sig-
niﬁcant (p’s ≥ 0.075). On ISI touch rate (Table 1), there
was a U-shaped dose-response (F3,42= 5.712, p= 0.031).
The 40mg/kg dose increased ISI touch rate relative to
vehicle (p= 0.050) and the 0.04 mg/kg dose (p= 0.005).
Modaﬁnil in both wild-type and Df(h22q11)/+ mice
When the data were speculatively analyzed across both
genotypes, we observed a signiﬁcant impairment in
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Fig. 2 Performance of Df(h22q11)/ + and wild-type littermates on the 2-stimulus training stage 3 and the baseline 5-stimulus rCPT.
Performance of Df(h22q11)/+ and wild-type littermates on the 2-stimulus training stage 3 and the baseline 5-stimulus rCPT). Data are presented as
means ± SEM. Discrimination sensitivity (d’) is an index of the subject’s ability to distinguish target from non-target stimuli, while response criterion (c)
describes the subject’s propensity to respond to any stimulus. a 2-stimulus: d’ and c. Df(h22q11)/+ mice had increased response criterion c. Df
(h22q11)/+ mice showed a non-signiﬁcant decrease in d’ (p= 0.051) relative to littermate controls. b 2-stimulus: hit rate and false alarm rate. Df
(h22q11)/+ mice had decreased hit rates relative to controls. There was no effect of genotype on false alarm rate. c 5-stimulus rCPT: d’ and c. Df
(h22q11)/+ mice had decreased d’ relative to controls. There was no effect of genotype on response criterion. d 5-stimulus rCPT: hit rate and false
alarm rate. Df(h22q11)/+ mice showed decreased hit rate relative to controls. There was no effect of genotype on false alarm rate. Asterisk denotes
signiﬁcant effect of genotype (*p < 0.05)
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discrimination sensitivity (d’) in Df(h22q11)/+ relative to
wild-type mice (Fig. 4a; F1,26= 6.781, p= 0.015). There
were no effects of modaﬁnil on d’ (Fig. 4a). On incorrect
response latency, there was a genotype × dose interaction
(Table 1; genotype × dose: F3,78= 3.263, p= 0.026). In Df
(h22q11)/+ mice, the highest 40 mg/kg dose reduced
incorrect response latency relative to vehicle (p < 0.0001).
This reduction was not present in wild-type animals (p=
0.920).
Modaﬁnil exerted U-shaped dose-response effects on
false alarm rate across both genotypes (Fig. 4b; dose: F3,78
= 2.964, p= 0.037, quadratic effect: F1,26= 5.335, p=
0.029). The 40mg/kg dose signiﬁcantly reduced false
alarm rate relative to the 4 mg/kg dose (p= 0.028).
Fig. 3 PFC and hippocampal synchrony and power spectra of Df(h22.q11)/+and wild-type littermates. Data are presented as mean ± SEM.
Shaded areas represent SEM. a Left: Representative traces of the LFP recorded from the same animal simultaneously in the PFC and dorsal
hippocampus during steady state conditions. Raw traces are plotted in gray and theta-ﬁltered traces are overlaid in black. Right: Schematic diagram
showing locations of LFP recording. b Averaged power spectra for each structure (PFC: left, HPC: middle) and average PFC-hippocampal coherence in
0.1–25 Hz range (right) in Df(h22.q11)/+ and wild-type littermates. c Average PFC-hippocampal coherence in 0.1–100 Hz range (same as b). Asterisk
denotes signiﬁcant effect of genotype (*p < 0.05, **p < 0.005, ***p < 0.0005)
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Modaﬁnil also produced U-shaped dose-responses in
both genotypes on ISI touch rate (Table 1; dose: F3,78=
8.128, p < 0.0001, quadratic effect: F1,26= 6.708, p=
0.016). Relative to vehicle, the 0.4 mg/kg dose reduced ISI
touch rate (p= 0.034) while the 40mg/kg dose increased
ISI touch rate (p= 0.015).
Amphetamine in the 22q11.2 model
In Df(h22q11)/+ mice, amphetamine increased dis-
crimination sensitivity (d’). On d’ (Fig. 4c), there was a
signiﬁcant linear effect of dose (F1,14= 6.683, p= 0.022)
with amphetamine dose-dependently improving d’. Relative
to vehicle, 1.0mg/kg amphetamine increased d’ (p= 0.018).
Amphetamine in both wild-type and Df(h22q11)/+ mice
When the data were analyzed across both genotypes,
the performance-enhancing effect of amphetamine on
discrimination sensitivity (d’) was not signiﬁcant (Fig. 4c;
see Supplementary Table S5 for statistical analyses).
However, a signiﬁcant dose-linear response-reducing
effects of amphetamine on ISI touch rate was observed
across both genotypes (Table 1; dose: F3,78= 3.793, p=
0.014, linear effect: F1,26= 8.551, p= 0.007). Relative to
vehicle, 1 mg/kg of amphetamine decreased ISI touch rate
(p= 0.006).
There was also a genotype × dose interaction on hit rate
(Fig. 4d; F3,78= 3.037, p= 0.034). In wild-type animals,
the highest 1.0 mg/kg dose caused a reduction in hit rate
relative to the 0.5 mg/kg dose (p= 0.046). This reduction
was not present in Df(h22q11)/+ mice (p= 0.848). There
was a dose-linear effect of amphetamine on false alarm
rate (Fig. 4d; F1,26= 4.629, p= 0.041). Relative to vehicle,
1.0 mg/kg amphetamine decreased false alarm rates across
both genotypes (p= 0.025). There was also a main effect
of dose on response criterion (c) (Fig. 4c; F3,78= 2.779, p
= 0.047). However post-hoc analyses comparing each
dose were not signiﬁcant (p’s ≥ 0.058).
Progressive ratio
PR performance for Df(h22q11)/+ mice and wild-type
littermates is presented in Fig. 5. There was no effect of
genotype on break-point (genotype: F1,29= 0.882, p=
0.355, genotype × PR schedule: F3,87= 0.603, p= 0.615) or
any other performance measurement (p ≥ 0.096; data not
shown).
Discussion
The present study revealed that the 22q11.2DS mouse
model (Df(h22q11)/+) exhibits neuropsychiatric disease-
relevant impairments in focused visual attention. Similar
Fig. 4 Performance of Df(h22q11)/ + and wild-type littermates on the 5-stimulus rCPT when treated with acute systemic modaﬁnil and
amphetamine. Performance of Df(h22q11)/+ and wild-type littermates on the 5-stimulus rCPT when treated with acute systemic modaﬁnil and
amphetamine). Data are presented as means ± SEM. Discrimination sensitivity (d’) is an index of the subject’s ability to distinguish target from non-
target stimuli, while response criterion (c) describes the subject’s propensity to respond to any stimulus. a Modaﬁnil: d’ and c. Modaﬁnil caused a
dose-linear decrease in d’ in the Df(h22q11)/+ model. There was no effect of modaﬁnil on response criterion c. b Modaﬁnil: hit rate and false alarm
rate. Modaﬁnil had no signiﬁcant effects on hit rate or false alarm rate. c Amphetamine: d’ and c. Amphetamine caused a dose-linear increase in d’ in
the Df(h22q11)/+ model. 1.0 mg/kg amphetamine tended to increase c in control animals only. d Amphetamine: hit rate and false alarm rate.
Amphetamine reduced hit rate in control animals only at the 1.0 mg/kg dose. Amphetamine caused a genotype-independent reduction in hit rate at
the 1.0 mg/kg dose. Pink shading denotes signiﬁcant dose-linear effect that were selective to the Df(h22q11)/+ model (Ψ= p < 0.05). Asterisk
denotes signiﬁcant main effect of genotype (*= p < 0.05). Gray shading and hash denote signiﬁcant genotype-independent dose differences (#= p
< 0.05). Grey shading and lambda denote signiﬁcant dose differences in Df(h22q11)/+ model (λ= p < 0.05). ‘V’ denotes drug vehicle condition
(modaﬁnil: saline+ 0.5% arabic gum, amphetamine: saline)
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rCPT impairments were observed across two cohorts that
differed in age and experimental training history. These
impairments in the 22q11.2DS model occurred in the
absence of motivational, motoric, visual or other cognitive
changes23, indicative of highly selective deﬁcits in visual
attentional control. Parallel with these behavioral
abnormalities, the 22q11.2DS mouse model showed
reduced PFC-hippocampal oscillatory synchrony in
gamma, delta, and theta bands, without altered basal
oscillatory activity within each region. The model deﬁcits
in discrimination sensitivity (d’) were dose-dependently
improved by acute, low-dose amphetamine and, contrary
to our predictions, dose-dependently impaired by acute
modaﬁnil treatment. Taken together, these data indicate a
robust, selective, translationally-relevant attentional
impairment in a 22q11.2DS mouse model that closely
mirrors a key cognitive endophenotypic marker of
22q11.2DS and related psychiatric disorders.
Attentional dysfunction in the Df(h22q11)/+ mouse
Attentional deﬁcits are central to 22q11.2DS sympto-
matology49. Individuals with 22q11.2DS show CPT
impairments7,10,12,50 and 30–40% of 22q11.2 deletion
Fig. 5 Performance of Df(h22q11)/+ and wild-types littermates
on progressive ratio schedules. Data are presented as means ± SEM.
There was no effect of genotype on break-point
Table 1 Mean response latencies and ISI touch rate of Df(h22q11)+ mice and wild-types littermate controls when
treated with acute systemic modaﬁnil and acute systemic amphetamine in the rCPT
etarhcuotISI
(per min) 
Correct response latency 
(ms) 
Incorrect response latency 
(ms) 
Reward retrieval latency 
(ms) 
Drug  
WT Df
(h22q11)/+
WT Df
(h22q11)/+
WT Df
(h22q11)/+
WT Df 
(h22q11)/+
Modafinil (mg/kg)
0 4.92±0.58 4.53±0.56 907±43 915±47 913±75 931±64 1007±34 1068±28
0.4 4.04±0.49 3.77±0.62 902±31 908±49 904±92 869±59 1016±41 1048±31
4.0 5.02±0.58 3.60±0.54 885±27 944±53 820±94 1049±75 999±37 1065±29
40 7.08±0.99 6.37±1.18 900±33 952±67 907±67 762±68** 956±30 1099±77
Amphetamine  
(mg/kg) 
0 3.35±0.54 3.10±0.67 947±80.6 896±84 974±90 933±60 973±32 1004±27
0.25 3.08±0.43 3.03±0.71 1066±68 892±42 917±49 980±91 977±28 1014±38
0.5 3.11±0.50 2.16±0.38 893±56 926±58 1083±82 810±87 1016±49 1026±37
1.0 1.86±0.48 1.92±0.35 972±92 943±72 1036±41 964±48 1113±100 1077±91
p < 
 0.05 Sig. increase from 
vehicle 
  0.05 Sig. decrease from 
probe vehicle  0.01 
 Color code denotes significant genotype-independent effects of drug dose. Please see legend for significance levels.  
 **Significant decrease in Df(h22q11)/+ mice relative to vehicle (p <0.0001).  
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carriers are diagnosed with schizophrenia1 or ADHD3,
disorders where CPT impairments represent core endo-
phenotypes51,52. Individuals with 22q11.2DS, as well as
with schizophrenia and ADHD, typically show decreased
discrimination sensitivity (d’)7,9.
Deﬁcits were observed in two separate cohorts of Df
(h22q11)/+ mice that varied in both age (5 vs. 16 months
at the start of testing) and previous cognitive testing
experience. Although the impairments in the older cohort
were somewhat less pronounced—found only under task
conditions which taxed attentional load (i.e., reduced
stimulus duration or increased inter-stimulus interval)—it
is notable that both cohorts showed selective impairments
in target hit rate. The wide age-range and relative
robustness of the Df(h22q11)/+ deﬁcits further reinforce
the translational relevance of the model on the rCPT
paradigm. Longitudinal studies have shown that CPT
attentional impairments can persist in 22q11.2DS7, schi-
zophrenia53, and ADHD54 and might represent a key
endophenotypic marker of these disorders29,55,56.
The Df(h22q11)/+ mice appear to have cognitive deﬁ-
cits on the rCPT that are speciﬁc to attentional processes.
We also demonstrate that Df(h22q11)/+ mice have intact
motivation in a touchscreen progressive ratio task. No
persistent impairment was previously observed in the
model using a large cognitive testing battery23, and studies
of cognition in alternative 22q11.2DS mouse models have
generally yielded mixed results (see Table 1 in ref. 23).
This is in apparent disparity with the clinical syndrome
which has been associated with widespread and often
non-selective cognitive impairment57. It is possible that
the selective attentional impairment of the 22q11.2DS
mouse model might require interaction with certain
environmental risk factors to induce a more profound
phenotype58,59. There are currently no reports assessing
the effects of environmental manipulations on cognitive
function in 22q11.2DS mouse models.
The mechanisms underlying impaired attention in
22q11.2DS are unknown49. Imaging studies of individuals
with 22q11.2.DS show abnormalities within brain net-
works supporting attention, including structural60,61 and
connectivity deﬁcits61,62 within and between the striatum,
PFC, cingulate, and temporal cortices. Structural deﬁcits
in the dorsolateral PFC and cingulate cortices of 22q11.2
deletion carriers correlate with CPT impairments10.
Immuno-, electrophysiological- and imaging assays
revealed PFC abnormalities in other 22q11.2DS models63–
65. Such abnormalities include PFC-hippocampal theta
and gamma coherence disruptions that correlate with the
slower learning in a T-maze task20,24.
We observed similar coherence abnormalities in the
current study using a 22q11.2DS model on a different
background strain and employing a different recording
environment (under immobile conditions). The results
validate the ﬁndings of previous reports20,24, and addi-
tionally demonstrate that the presence of PFC-HPC
asynchrony in the 22q11.2DS model is unrelated to cog-
nitive training and ongoing behavioral performance. PFC-
hippocampal synchrony aberrations may represent dis-
rupted longer-range information integration/coordination
in schizophrenia32, and the presence of similar disruptions
in Df(h22q11)/+ mice may support its validity for evalu-
ating genetic causes for psychopathology.
Pharmacological effects
Modaﬁnil and amphetamine can improve cognitive
functions in humans66–68 and experimental animals42,69–
72. The drugs nevertheless have both common and dis-
tinct biochemical effects68. The vigilance-promoting
effects of amphetamine have been attributed primarily
to increased dopamine/noradrenaline activity in pre-
frontal systems33, whereas modaﬁnil has additional
actions on serotonin, hypocretin/orexin, glutamate, his-
tamine and acetylcholine functions68. Our data indicate
that acute treatment with these drugs exerts modest but
bidirectional effects on attentional performance in Df
(h22q11)/+ mice.
Modaﬁnil
We observed a small but signiﬁcant reduction in dis-
crimination sensitivity (d’) following acute modaﬁnil treat-
ment in the Df(h22q11)/+ model. This linear dose-
dependent reduction in d’ was concomitant with speeding
of incorrect response latency. An impairing effect of 40mg/
kg modaﬁnil on d’ in the Df(h22q11)/+ model is similar to
the observed higher-dose effects (64mg/kg) on the rCPT in
the MAM-E17 rat model of schizophrenia31. It is also
consistent with the higher-dose effects of modaﬁnil
(64–100mg/kg) observed in other tests of attention and/or
inhibitory control, including decreased accuracy73 and
increased premature responding in the 5-CSRTT73,74 and
impaired Go-accuracy in the stop-signal reaction time
task43. Low-to-moderate doses of modaﬁnil have never-
theless been shown to improve stop-signal reaction time
(10mg/kg43) and CPT d’ in healthy rats (8mg/kg)31 and
fronto-striatal dependent cognition, including attention, in
humans (100–200mg75–77). Unlike amphetamine,
modaﬁnil-induced improvements have generally been
ascribed to enhanced inhibitory control processes that are
detected in low-performing sub-groups and/or when task
conditions are implemented that further challenge the
ability to withhold responses31,77. Amphetamine has higher
potency at dopamine/noradrenaline transporters than
modaﬁnil;78 suggesting that modaﬁnil’s impairing effects
involve additional transmitter systems. For example, mod-
aﬁnil, but not low-dose amphetamine, increases PFC 5-HT
levels79. Such 5-HT increases may produce detrimental
effects on impulsive-like behavior and attention when
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concurrent with elevations in striatal dopaminergic
tone80,81, as displayed by the Df(h22q11)/+ model39.
The lack of facilitatory effects from lower-dose mod-
aﬁnil in the present study might be explained by the fact
that, at the current task parameters, animals had low false
alarm rates (~ 0.1) and thus, ﬂoor-effects could preclude
detection of cognitive-enhancing effects of modaﬁnil. By
contrast, reduced baselines for false alarms would not
prevent psychostimulants such as amphetamine and
methylphenidate - which also enhance hit rates38 - from
exerting performance-enhancing effects. Task parameters
that challenge inhibitory control processes (e.g., variable
ISIs, SDs, CS+ probabilities, ﬂanking distractors) may be
more amenable for uncovering pro-cognitive effects from
low-dose modaﬁnil in the rCPT, as was observed in the
rat using variable SDs and ISIs31.
Amphetamine
We observed a signiﬁcant, dose-dependent, enhance-
ment of discrimination sensitivity (d’) in Df(h22q11)/+
animals treated with amphetamine. This improvement is
in translational agreement with data showing that acute
administration of the mechanistically-similar stimulant,
methylphenidate, can improve d’ in children and adoles-
cents with 22q11.2DS on a visual CPT paradigm37. The
data are consistent with reports of low-dose stimulants
improving CPT d’ in ADHD82 and the performances of
individuals with schizophrenia on CPT-like tasks83,84. It is
also in line with rodent studies in which low-dose
amphetamine (0.25–0.5 mg/kg) or methylphenidate
(2.0 mg/kg) improves attentional accuracy on serial reac-
tion time tasks in low-attentive animals or animals chal-
lenged with short SDs42,72,85.
The amphetamine-induced improvements in d’ in Df
(h22q11)/+ mice are due to the combined inﬂuence of
increasing target hit rate and decreasing non-target false
alarm rate, with neither measure showing signiﬁcant
changes on their own. This enhancement in d’ was
accompanied by a signiﬁcant reduction in the rate of
extraneous touches within the response window on the
screen during the ISI (in the absence of any stimuli).
Together, the effects of higher discrimination sensitivity (d’)
and reduced extraneous responding indicate that amphe-
tamine dose-dependently enhances global task performance
‘efﬁciency’. This may reﬂect a unitary enhancement of
attentional control or may be the result of improvements
across several distinct cognitive dimensions, including
attentional processing (i.e., increases in hit rate and d’) and
hyperactivity/impulsivity (i.e., decreases in false alarm and
ISI touch rate)86. Further work investigating the cognitive
mechanisms underlying the performance-enhancing effects
of amphetamine is warranted.
The cognitive-enhancing effects of low-dose psychosti-
mulant treatment in the Df(h22q11)/+ model may be
produced by preferential activity within the PFC, where
concerted actions at noradrenaline transporters and D1/α2
receptors cause downstream glutamatergic and
GABAergic events that increase neuronal tuning to
behaviorally relevant stimuli33,87. Higher doses, however,
have qualitatively different effects from lower doses and
consequent deﬁcits in signal processing33,87. Thus, in
contrast to the clear cognitive-enhancing effects of
amphetamine on rCPT performance in Df(h22q11)/+
mice, the highest dose (1.0 mg/kg) of amphetamine
exerted response-suppressant effects in wild-type animals.
This effect was seen as a decrease across all response
rates, including hit rate, false alarm rate and the rate of ISI
responses. There was an associated increase in response
criterion without changes in d’. Similar suppressant effects
of amphetamine have been observed in healthy well-
trained rodents in the 5-CSRTT using comparable doses
(≥ 0.8 mg/kg)69,88,89. The distinct effects of 1 mg/kg
amphetamine on rCPT performance between Df
(h22q11)/+ and wild-type mice (i.e., improvement rather
than impairment) might be explained by the model’s
hemizygosity for catecholamine-O-methyl transferase
(COMT). COMT is involved in dopamine degradation
primarily in regions with low expression of dopamine
transporters, including the PFC90. In healthy rodents,
higher-dose (1–1.5 mg/kg) amphetamine has potent
effects on striatal relative to PFC dopamine levels91,92
which can have mild stimulant effects93,94 and alters
motivational processes95. Decreased COMT dosage in the
22q11.2DS model could increase the ratio of PFC:striatum
dopamine transmission following amphetamine treat-
ment, resulting in increased prefrontal, task-speciﬁc,
cognitive control and in fewer striatally-mediated motoric
and/or motivationally-related side effects33. Evidence for
such an altered PFC:striatum dopamine ratio has been
observed in COMT+/- mice after amphetamine (2.5 mg/
kg) treatment, resulting in higher PFC:striatal dopamine
turnover compared to wild-type controls96. COMT
hemizygosity might additionally reduce degradation of
amphetamine-induced norepinephrine release97,98 which,
within the demanding rCPT paradigm, might also con-
tribute to the relative absence of a response-suppressant
effect of 1.0 mg/kg amphetamine in the Df(h22q11)/+
mouse.
The contrasting effects of amphetamine and modaﬁnil
on discrimination sensitivity (d’) in the rCPT might be
related to differences in the chosen doses within the
employed dose ranges, and/or suggest key differences in
the relevant cognition-enhancing mechanisms. It would
also be valuable to investigate the effects of sub-chronic/
chronic dosing of these compounds to evaluate the sta-
bility of the pharmacological effects on task performance.
Regardless, it is notable that both compounds inﬂuence
the d’ measure, an index widely linked to attentional
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performance in the human CPT paradigm, selectively in
Df(h22q11)/+ mice. The two drugs have been previously
shown to exert neurochemical and electrophysiological
modulatory effects within and between the PFC and
hippocampus33,99. One limitation of the present study is
that we did not examine drug effects on PFC-
hippocampal coherence. It would be interesting to
examine speciﬁc drug effects on PFC-hippocampal
coherence in the Df(h22q11)/+ model—both indepen-
dent of behavioral testing, and whilst systematically
varying the cognitive demand of the rCPT during various
dose regiments—to establish the potential role of elec-
trophysiological correlates in our observed differences in
attentional function.
Conclusions
We demonstrate that a 22q11.2DS mouse model has
selective impairments on a translationally relevant rCPT
test of attention. These impairments are dose-
dependently ameliorated by acute amphetamine treat-
ment. These data closely parallel reported CPT
impairments in 22q11.2 deletion carriers that are ame-
liorated by the psychostimulant, methylphenidate. The
observed behavioral impairments were paralleled by
PFC-hippocampal coherence disruptions within delta,
theta and gamma bands during non-task conditions.
This is the ﬁrst report of attentional impairment in a
22q11.2DS model; we have demonstrated a translational
utility of the Df(h22q11)/+ mouse in a fully automated
and high-throughput procedure that permits large-scale
and simultaneous cognitive assessment of multiple
animals. In the context of the relatively limited
pathology-like phenotypes that have been detected in
the Df(h22q11)/+ mouse using alternative cognitive
paradigms23, the rCPT may be a useful translational tool
with enhanced sensitivity for detecting dysfunctions in
rodent models.
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